Kristen Yen - 21 Jan 2026 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role: Officer title: SVP Global Clinical Operations and Patient Advocacy
Signature: /s/ Anish Bhatnagar, Attorney-in-Fact
Issuer symbol: SLNO
Transactions as of: 21 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 23 Jan 2026, 18:08:14 UTC
Previous filing: 17 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Yen Kristen	Officer title: SVP Global Clinical Operations and Patient Advocacy	100 MARINE PARKWAY, SUITE 400, REDWOOD CITY	/s/ Anish Bhatnagar, Attorney-in-Fact	23 Jan 2026	0001643441

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLNO	Common Stock	Award	$0	+10,400	+38%	$0.000000	37,639	21 Jan 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLNO	Employee stock option (right to buy)	Award	$0	+11,900		$0.000000	11,900	21 Jan 2026	Common Stock	11,900	$43.65	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.
F2	Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3	1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

Remarks:

Officer title: SVP Global Clinical Operations and Patient Advocacy